Article
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
The oncologist - 4 Mar 2024
Albuquerque Joana, Neto da Silva Diana, Padrão Teresa, Leal-Costa Luísa, Bizarro Rita, Correia Jorge, Baptista Carlota, Machete Madalena, Prazeres Gil, Margarido Inês, Fernandes Gonçalo, Simões Pedro, Timóteo Teresa, Lopes Fábio, Godinho João, Moreira-Pinto João, Rodrigues Tânia, Faria Ana, Pulido Catarina, Cirnes Luís, Teixeira José A, Passos Coelho José L
Abstract excerpt
BACKGROUND: Liquid biopsy (LB) is a non-invasive tool to evaluate the heterogeneity of tumors. Since RAS mutations (RAS-mut) play a major role in resistance to antiepidermal growth factor receptor inhibitors (EGFR) monoclonal antibodies (Mabs), serial monitoring of RAS-mut with LB may be useful to guide treatment. The main aim of this study was to evaluate the prognostic value of the loss of RAS-mut (NeoRAS-wt)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.